learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forLearn
1 / 1 resultsResearch
5 / 400 results
research Androgen Receptor Modulators: A Review of Recent Patents and Reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
research What's New in Therapy for Male Androgenetic Alopecia?
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
Community Join
5 / 400 resultscommunity Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
community Kintor Pharmaceutical Announced U.S. FDA Has Greenlighted Phase II Clinical Trial for Pyrilutamide to Treat Androgenetic Alopecia
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Pyrilutamide kintor pharmaceutical
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.